Iris Biotechnologies Inc (IRSB) financial statements (2021 and earlier)

Company profile

Business Address 5201 GREAT AMERICA PARKWAY
SANTA CLARA, CA 95054
State of Incorp. NY
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments10810205245179
Cash and cash equivalents10810205245179
Prepaid expense  14   
Total current assets:10811235245179
Noncurrent Assets
Property, plant and equipment24262830423411
Total noncurrent assets:24262830423411
TOTAL ASSETS:333339539479190
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:13095140124175120161
Accounts payable    175120161
Other undisclosed accounts payable and accrued liabilities13095140124   
Debt1515   25
Derivative instruments and hedges, liabilities   169   
Due to related parties29126123017510000
Deferred revenue and credits8      
Total current liabilities:443372371469276122166
Noncurrent Liabilities
Long-term debt and lease obligation   26   
Long-term debt, excluding current maturities   26   
Liabilities, other than long-term debt    10000
Due to related parties    10000
Other undisclosed noncurrent liabilities212126 (74)2626
Total noncurrent liabilities:21212626262626
Total liabilities:464393397495302148192
Stockholders' equity
Stockholders' equity attributable to parent(431)(359)(358)(441)(208)(69)(2)
Common stock9,0318,8958,8918,8518,5938,5808,508
Common stock, share subscribed but unissued, subscriptions receivable(128)(128)(128)(128)(128)(128)(128)
Additional paid in capital3,5843,5783,3962,8782,8852,8292,768
Accumulated deficit(12,917)(12,704)(12,516)(12,042)(11,558)(11,350)(11,149)
Total stockholders' equity:(431)(359)(358)(441)(208)(69)(2)
TOTAL LIABILITIES AND EQUITY:333339539479190

Income statement (P&L) ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Gross profit:1      
Operating expenses(212)(188)(185)(371)(207)(200)(280)
Operating loss:(212)(188)(185)(371)(207)(200)(280)
Nonoperating expense
(Other Nonoperating expense)
(1)(1)(288)    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (115)   
Net loss:(212)(189)(474)(486)(207)(200)(280)
Other undisclosed net income (loss) attributable to parent   2(1)(0)(1)
Net loss available to common stockholders, diluted:(212)(189)(474)(485)(207)(201)(280)

Comprehensive Income ($ in thousands)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Net loss:(212)(189)(474)(486)(207)(200)(280)
Other comprehensive income  7    
Other undisclosed comprehensive loss   (56)   
Comprehensive loss, net of tax, attributable to parent:(212)(189)(467)(543)(207)(200)(280)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: